Biological basis for increased sensitivity to radiation therapy in HPV-positive head and neck cancers

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Bol, V ^a   Gregoire V ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ONCOPROTEIN; PROTEIN P16; UNCLASSIFIED DRUG; VIRAL PROTEIN E6; VIRAL PROTEIN E7; VIRUS PROTEIN;

ALCOHOL CONSUMPTION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CARCINOGENESIS; CLINICAL TRIAL (TOPIC); GENE OVEREXPRESSION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; IMMUNE RESPONSE; NONHUMAN; PAPILLOMAVIRUS INFECTION; RADIOSENSITIVITY; REVIEW; TOBACCO CONSUMPTION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; WART VIRUS; BIOSYNTHESIS; CARCINOMA, SQUAMOUS CELL; GENE EXPRESSION REGULATION; GENETICS; HEAD AND NECK NEOPLASMS; METABOLISM; PAPILLOMA VIRUS; PAPILLOMAVIRUS INFECTIONS; PATHOLOGY; RADIATION DOSE; VIROLOGY;

CARCINOMA, SQUAMOUS CELL; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; RADIATION TOLERANCE;

EID: 84899499283     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/696028     Document Type: Review

References (71)

1. Gillison M. L., Koch W. M., Capone R. B., Spafford M., Westra W. H., Wu L., Zahurak M. L., Daniel R. W., Viglione M., Symer D. E., Shah K. V., Sidransky D., Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. Journal of the National Cancer Institute 2000 92 9 709 720 2-s2.0-0034600339 (Pubitemid 30365531)
2. Andl T., Kahn T., Pfuhl A., Nicola T., Erber R., Conradt C., Klein W., Helbig M., Dietz A., Weidauer H., Bosch F. X., Etiological involvement of oncogenic human papillomavirus in tonsillar squamous cell carcinomas lacking retinoblastoma cell cycle control. Cancer Research 1998 58 1 5 13 2-s2.0-0031964379 (Pubitemid 28027707)
3. Argiris A., Karamouzis M. V., Raben D., Ferris R. L., Head and neck cancer. The Lancet 2008 371 9625 1695 1709 2-s2.0-43449132987 10.1016/S0140-6736(08)60728-X (Pubitemid 351671886)
4. D'Souza G., Kreimer A. R., Viscidi R., Pawlita M., Fakhry C., Koch W. M., Westra W. H., Gillison M. L., Case-control study of human papillomavirus and oropharyngeal cancer. The New England Journal of Medicine 2007 356 19 1944 1956 2-s2.0-34248350674 10.1056/NEJMoa065497 (Pubitemid 46740304)
5. Gillison M. L., Alemany L., Snijders P. J. F., Chaturvedi A., Steinberg B. M., Schwartz S., Castellsagué X., Human papillomavirus and diseases of the upper airway: head and neck cancer and respiratory papillomatosis. Vaccine 2012 30 supplemet 5 F34 F54 10.1016/j.vaccine.2012.05.070
6. Muñoz N., Bosch F. X., de Sanjosé S., Herrero R., Castellsagué X., Shah K. V., Snijders P. J., Meijer C. J., International Agency for Research on Cancer Multicenter Cervical Cancer Study Group, Epidemiologic classification of human papillomavirus types associated with cervical cancer. The New England Journal of Medicine 2003 348 6 518 527 (Pubitemid 36159887)
7. Kreimer A. R., Clifford G. M., Boyle P., Franceschi S., Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systemic review. Cancer Epidemiology Biomarkers and Prevention 2005 14 2 467 475 2-s2.0-13944263935 10.1158/1055-9965.EPI-04-0551 (Pubitemid 40270113)
8. Lassen P., Eriksen J. G., Hamilton-Dutoit S., Tramm T., Alsner J., Overgaard J., Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. Journal of Clinical Oncology 2009 27 12 1992 1998 2-s2.0-65349173893 10.1200/JCO.2008.20.2853
9. Fakhry C., Westra W. H., Li S., Cmelak A., Ridge J. A., Pinto H., Forastiere A., Gillison M. L., Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. Journal of the National Cancer Institute 2008 100 4 261 269 2-s2.0-39649109915 10.1093/jnci/djn011 (Pubitemid 351480538)
10. Licitra L., Perrone F., Bossi P., Suardi S., Mariani L., Artusi R., Oggionni M., Rossini C., Cantù G., Squadrelli M., Quattrone P., Locati L. D., Bergamini C., Olmi P., Pierotti M. A., Pilotti S., High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. Journal of Clinical Oncology 2006 24 36 5630 5636 2-s2.0-34247331367 10.1200/JCO.2005.04.6136 (Pubitemid 46631302)
11. Weinberger P. M., Yu Z., Haffty B. G., Kowalski D., Harigopal M., Sasaki C., Rimm D. L., Psyrri A., Prognostic significance of p16 protein levels in oropharyngeal squamous cell cancer. Clinical Cancer Research 2004 10 17 5684 5691 2-s2.0-4444288693 10.1158/1078-0432.CCR-04-0448 (Pubitemid 39180943)
12. Petrelli F., Sarti E., Barni S., Predictive value of human papillomavirus in oropharyngeal carcinoma treated with radiotherapy: an updated systematic review and meta-analysis of 30 trials. Head and Neck 2013 10.1002/hed.23351
13. Braakhuis B. J. M., Snijders P. J. F., Keune W.-J. H., Meijer C. J. L. M., Ruijter-Schippers H. J., Leemans C. R., Brakenhoff R. H., Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus. Journal of the National Cancer Institute 2004 96 13 998 1006 2-s2.0-3242670907 (Pubitemid 39162642)
14. Doorbar J., Quint W., Banks L., Bravo I. G., Stoler M., Broker T. R., Stanley M. A., The biology and life-cycle of human papillomaviruses. Vaccine 2012 30 supplement 5 F55 F70 10.1016/j.vaccine.2012.06.083
15. McLaughlin-Drubin M. E., Münger K., Oncogenic activities of human papillomaviruses. Virus Research 2009 143 2 195 208 2-s2.0-68949194550 10.1016/j.virusres.2009.06.008
16. Jabbar S., Strati K., Shin M. K., Pitot H. C., Lambert P. F., Human papillomavirus type 16 E6 and E7 oncoproteins act synergistically to cause head and neck cancer in mice. Virology 2010 407 1 60 67 2-s2.0-77956914783 10.1016/j.virol.2010.08.003
17. Jastreboff A. M., Cymet T., Role of the human papilloma virus in the development of cervical intraepithelial neoplasia and malignancy. Postgraduate Medical Journal 2002 78 918 225 228 2-s2.0-0036215145 10.1136/pmj.78.918.225 (Pubitemid 34293323)
18. Rampias T., Sasaki C., Weinberger P., Psyrri A., E6 and E7 gene silencing and transformed phenotype of human papillomavirus 16-positive oropharyngeal cancer cells. Journal of the National Cancer Institute 2009 101 6 412 423 2-s2.0-65349107653 10.1093/jnci/djp017
19. Scheffner M., Werness B. A., Huibregtse J. M., Levine A. J., Howley P. M., The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990 63 6 1129 1136 2-s2.0-0025639158 10.1016/0092-8674(90)90409-8 (Pubitemid 120035062)
20. Bernard X., Robinson P., Nominé Y., Masson M., Charbonnier S., Ramirez-Ramos J. R., Deryckere F., Travé G., Orfanoudakis G., Proteasomal degradation of p53 by human papillomavirus E6 oncoprotein relies on the structural integrity of p53 core domain. PLoS ONE 2011 6 10 2-s2.0-80055034154 10.1371/journal.pone.0025981 e25981
21. Kessis T. D., Slebos R. J., Nelson W. G., Kastan M. B., Plunkett B. S., Han S. M., Lorincz A. T., Hedrick L., Cho K. R., Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. Proceedings of the National Academy of Sciences of the United States of America 1993 90 9 3988 3992 2-s2.0-0027266971 (Pubitemid 23134151)
22. Yamada T., Yamashita T., Nishikawa T., Fujimoto S., Fujinaga K., Biologic activity of human papillomavirus type 16 E6/E7 cDNA clones isolated from SiHa cervical carcinoma cell line. Virus Genes 1995 10 1 15 25 2-s2.0-0029040313 10.1007/BF01724293
23. James M. A., Lee J. H., Klingelhutz A. J., HPV16-E6 associated hTERT promoter acetylation is E6AP dependent, increased in later passage cells and enhanced by loss of p300. International Journal of Cancer 2006 119 8 1878 1885 2-s2.0-33748497595 10.1002/ijc.22064 (Pubitemid 44356846)
24. Kiyono T., Foster S. A., Koop J. I., McDougall J. K., Galloway D. A., Klingelhutz A. J., Both Rb/p16(INK4a) inactivation and telomerase activity are required to immortalize human epithelial cells. Nature 1998 396 6706 84 88 2-s2.0-0032487675 10.1038/23962 (Pubitemid 28520454)
25. Doorbar J., The papillomavirus life cycle. Journal of Clinical Virology 2005 32 S7 S15 2-s2.0-14744285753 10.1016/j.jcv.2004.12.006 (Pubitemid 40332584)
26. Strati K., Lambert P. F., Role of Rb-dependent and Rb-independent functions of papillomavirus E7 oncogene in head and neck cancer. Cancer Research 2007 67 24 11585 11593 2-s2.0-37549062918 10.1158/0008-5472.CAN-07-3007
27. Khleif S. N., Degregori J., Yee C. L., Otterson G. A., Kaye F. J., Nevins J. R., Howley P. M., Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity. Proceedings of the National Academy of Sciences of the United States of America 1996 93 9 4350 4354 2-s2.0-0029975913
28. Klaes R., Friedrich T., Spitkovsky D., Ridder R., Rudy W., Petry U., Dallenbach-Hellweg G., Schmidt D., von Doeberitz M. K., Overexpression of p16ink4a as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. International Journal of Cancer 2001 92 2 276 284 2-s2.0-0035871985 10.1002/ijc.1174 (Pubitemid 32225381)
29. Brehm A., Nielsen S. J., Miska E. A., McCance D. J., Reid J. L., Bannister A. J., Kouzarides T., The E7 oncoprotein associates with Mi2 and histone deacetylase activity to promote cell growth. EMBO Journal 1999 18 9 2449 2458 2-s2.0-0033522479 10.1093/emboj/18.9.2449 (Pubitemid 29213278)
30. Ang K. K., Sturgis E. M., Human papillomavirus as a marker of the natural history and response to therapy of head and neck squamous cell carcinoma. Seminars in Radiation Oncology 2012 22 2 128 142 2-s2.0-84857556316 10.1016/j.semradonc.2011.12.004
31. Martinive P., Defresne F., Bouzin C., Saliez J., Lair F., Grégoire V., Michiels C., Dessy C., Feron O., Preconditioning of the tumor vasculature and tumor cells by intermittent hypoxia: implications for anticancer therapies. Cancer Research 2006 66 24 11736 11744 2-s2.0-33846204728 10.1158/0008-5472.CAN- 06-2056 (Pubitemid 46094185)
32. Kinner A., Wu W., Staudt C., Iliakis G., Gamma-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin. Nucleic Acids Research 2008 36 17 5678 5694 2-s2.0-55249116558 10.1093/nar/gkn550
33. Eriksson D., Stigbrand T., Radiation-induced cell death mechanisms. Tumor Biology 2010 31 4 363 372 2-s2.0-77954641944 10.1007/s13277-010-0042-8
34. Rieckmann T., Tribius S., Grob T. J., Meyer F., Busch C.-J., Petersen C., Dikomey E., Kriegs M., HNSCC cell lines positive for HPV and p16 possess higher cellular radiosensitivity due to an impaired DSB repair capacity. Radiotherapy and Oncology 2013 107 2 242 246 10.1016/j.radonc.2013.03.013
35. Kimple R. J., Smith M. A., Blitzer G. C., Torres A. D., Martin J. A., Yang R. Z., Peet C. R., Lorenz L. D., Nickel K. P., Klingelhutz A. J., Lambert P. F., Harari P. M., Enhanced radiation sensitivity in HPV-positive head and neck cancer. Cancer Research 2013 73 15 4791 1800 10.1158/0008-5472.CAN-13-0587
36. Aldridge D. R., Arends M. J., Radford I. R., Increasing the susceptibility of the rat 208F fibroblast cell line to radiation-induced apoptosis does not alter its clonogenic survival dose-response. The British Journal of Cancer 1995 71 3 571 577 2-s2.0-0028929614
37. Kyprianou N., King E. D., Bradbury D., Rhee J. G., bcl-2 over-expression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cells. International Journal of Cancer 1997 70 3 341 348 10.1002/(SICI)1097-0215(19970127)70:3<341::AID-IJC16>3.0.CO;2-I (Pubitemid 27099605)
38. Wouters B. G., Giaccia A. J., Denko N. C., Brown J. M., Loss of p21(Waf1/Cip1) sensitizes tumors to radiation by an apoptosis-independent mechanism. Cancer Research 1997 57 21 4703 4706 2-s2.0-0030611754 (Pubitemid 27468970)
39. Wouters B. G., Denko N. C., Giaccia A. J., Brown J. M., A p53 and apoptotic independent role for p21(waf1) in tumour response to radiation therapy. Oncogene 1999 18 47 6540 6545 2-s2.0-0033547429
40. Dewey W. C., Ling C. C., Meyn R. E., Radiation-induced apoptosis: relevance to radiotherapy. International Journal of Radiation Oncology Biology Physics 1995 33 4 781 796 2-s2.0-0028846648 10.1016/0360-3016(95)00214-8
41. Deweese T. L., Walsh J. C., Dillehay L. E., Kessis T. D., Hedrick L., Cho K. R., Nelson W. G., Human papillomavirus E6 and E7 oncoproteins alter cell cycle progression but not radiosensitivity of carcinoma cells treated with low-dose-rate radiation. International Journal of Radiation Oncology Biology Physics 1997 37 1 145 154 2-s2.0-0031040705 10.1016/S0360-3016(96)00448-8 (Pubitemid 27090147)
42. Kamradt M. C., Mohideen N., Krueger E., Walter S., Vaughan A. T. M., Inhibition of radiation-induced apoptosis lay dexamethasone in cervical carcinoma cell lines depends upon increased HPV E6/E7. The British Journal of Cancer 2000 82 10 1709 1716 2-s2.0-0034012565 (Pubitemid 30229583)
43. Hampson L., El Hady E. S., Moore J. V., Kitchener H., Hampson I. N., The HPV16 E6 and E7 proteins and the radiation resistance of cervical carcinoma. The FASEB Journal 2001 15 8 1445 1447 2-s2.0-0035379570
44. Pang E., Delic N. C., Hong A., Zhang M., Rose B. R., Lyons J. G., Radiosensitization of oropharyngeal squamous cell carcinoma cells by human papillomavirus 16 oncoprotein E6I. International Journal of Radiation Oncology Biology Physics 2011 79 3 860 865 2-s2.0-79551505067 10.1016/j.ijrobp.2010.06. 028
45. Iftner T., Elbel M., Schopp B., Hiller T., Loizou J. I., Caldecott K. W., Stubenrauch F., Interference of papillomavirus E6 protein with single-strand break repair by interaction with XRCC1. EMBO Journal 2002 21 17 4741 4748 2-s2.0-0037009440 10.1093/emboj/cdf443 (Pubitemid 34984361)
46. Shin K.-H., Ahn J. H., Kang M. K., Lim P. K., Yip F. K., Baluda M. A., Park N.-H., HPV-16 E6 oncoprotein impairs the fidelity of DNA end-joining via p53-dependent and -independent pathways. International Journal of Oncology 2006 28 1 209 215 2-s2.0-33644791868
47. Yoshimura M., Itasaka S., Harada H., Hiraoka M., Microenvironment and radiation therapy. BioMed Research International 2013 2013 13 685308 10.1155/2013/685308
48. Lassen P., Eriksen J. G., Hamilton-Dutoit S., Tramm T., Alsner J., Overgaard J., The Danish Head and Neck Cancer Group (DAHANCA), HPV-associated p16-expression and response to hypoxic modification of radiotherapy in head and neck cancer. Radiotherapy and Oncology 2010 94 1 30 35 2-s2.0-74549123751 10.1016/j.radonc.2009.10.008
49. Kong C. S., Narasimhan B., Cao H., Kwok S., Erickson J. P., Koong A., Pourmand N., Le Q.-T., The relationship between human papillomavirus status and other molecular prognostic markers in head and neck squamous cell carcinomas. International Journal of Radiation Oncology Biology Physics 2009 74 2 553 561 2-s2.0-65449131740 10.1016/j.ijrobp.2009.02.015
50. Toustrup K., Sørensen B. S., Lassen P., Wiuf C., Alsner J., Overgaard J., The Danish Head and Neck Cancer Group (DAHANCA), Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck. Radiotherapy and Oncology 2012 102 1 122 129 2-s2.0-84455209531 10.1016/j.radonc.2011.09.010
51. Mortensen L. S., Johansen J., Kallehauge J., Primdahl H., Busk M., Lassen P., Alsner J., Sørensen B. S., Toustrup K., Jakobsen S., Petersen J., Petersen H., Theil J., Nordsmark M., Overgaard J., FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: results from the DAHANCA 24 trial. Radiotherapy and Oncology 2012 105 1 14 20 10.1016/j.radonc.2012.09.015
52. Sørensen B. S., Busk M., Olthof N., Speel E. J., Horsman M. R., Alsner J., Overgaard J., Radiosensitivity and effect of hypoxia in HPV positive head and neck cancer cells. Radiotherapy and Oncology 2013 108 3 500 505 10.1016/j.radonc.2013.06.011
53. Albers A., Abe K., Hunt J., Wang J., Lopez-Albaitero A., Schaefer C., Gooding W., Whiteside T. L., Ferrone S., DeLeo A., Ferris R. L., Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck. Cancer Research 2005 65 23 11146 11155 2-s2.0-28244456274 10.1158/0008-5472.CAN-05-0772 (Pubitemid 41713386)
54. Hoffmann T. K., Arsov C., Schirlau K., Bas M., Friebe-Hoffmann U., Klussmann J. P., Scheckenbach K., Balz V., Bier H., Whiteside T. L., T cells specific for HPV16 E7 epitopes in patients with squamous cell carcinoma of the oropharynx. International Journal of Cancer 2006 118 8 1984 1991 2-s2.0-33645215135 10.1002/ijc.21565
55. Smith E. M., Pawlita M., Rubenstein L. M., Haugen T. H., Hamsikova E., Turek L. P., Risk factors and survival by HPV-16 E6 and E7 antibody status in human papillomavirus positive head and neck cancer. International Journal of Cancer 2010 127 1 111 117 2-s2.0-77953453873 10.1002/ijc.25015
56. Uyttenhove C., Maryanski J., Boon T., Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression. Journal of Experimental Medicine 1983 157 3 1040 1052 2-s2.0-0020546609 (Pubitemid 13117080)
57. Maryanski J. L., Marchand M., Uyttenhove C., Boon T., Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. VI. Occasional escape from host rejection due to antigen-loss secondary variants. International Journal of Cancer 1983 31 1 119 123 2-s2.0-0020679048 (Pubitemid 13179560)
58. Dunn G. P., Bruce A. T., Ikeda H., Old L. J., Schreiber R. D., Cancer immunoediting: from immunosurveillance to tumor escape. Nature Immunology 2002 3 11 991 998 2-s2.0-0036852241 10.1038/ni1102-991 (Pubitemid 35363648)
59. Grabowska A. K., Riemer A. B., The invisible enemy-how human papillomaviruses avoid recognition and clearance by the host immune system. The Open Virology Journal 2012 6 249 256 10.2174/1874357901206010249
60. Piersma S. J., Jordanova E. S., van Poelgeest M. I. E., Kwappenberg K. M. C., van der Hulst J. M., Drijfhout J. W., Melief C. J. M., Kenter G. G., Fleuren G. J., Offringa R., van der Burg S. H., High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Research 2007 67 1 354 361 2-s2.0-33846444354 10.1158/0008-5472.CAN-06-3388 (Pubitemid 46142795)
61. Durante M., Reppingen N., Held K. D., Immunologically augmented cancer treatment using modern radiotherapy. Trends in Molecular Medicine 2013 19 9 565 582 10.1016/j.molmed.2013.05.007
62. McBride W. H., Chiang C.-S., Olson J. L., Wang C.-C., Hong J.-H., Pajonk F., Dougherty G. J., Iwamoto K. S., Pervan M., Liao Y.-P., A sense of danger from radiation. Radiation Research 2004 162 1 1 19 2-s2.0-3843124144 10.1667/RR3196 (Pubitemid 39044714)
63. Obeid M., Panaretakis T., Joza N., Tufi R., Tesniere A., van Endert P., Zitvogel L., Kroemer G., Calreticulin exposure is required for the immunogenicity of γ -irradiation and UVC light-induced apoptosis. Cell Death and Differentiation 2007 14 10 1848 1850 2-s2.0-34548576109 10.1038/sj.cdd.4402201 (Pubitemid 47423653)
64. Kepp O., Senovilla L., Galluzzi L., Panaretakis T., Tesniere A., Schlemmer F., Madeo F., Zitvogel L., Kroemer G., Viral subversion of immunogenic cell death. Cell Cycle 2009 8 6 860 869 2-s2.0-65349092744
65. Regan J. A., Laimins L. A., Bap31 is a novel target of the human papillomavirus E5 protein. Journal of Virology 2008 82 20 10042 10051 2-s2.0-53749089317 10.1128/JVI.01240-08
66. Tseng C. W., Monie A., Trimble C., Alvarez R. D., Huh W. K., Buchsbaum D. J., Straughn J. M. Jr., Wang M.-C., Yagita H., Hung C.-F., Wu T.-C., Combination of treatment with death receptor 5-specific antibody with therapeutic HPV DNA vaccination generates enhanced therapeutic anti-tumor effects. Vaccine 2008 26 34 4314 4319 2-s2.0-47649133239 10.1016/j.vaccine.2008. 06.049
67. Sin J.-I., Kim J.-M., Bae S. H., Lee I., Park J. S., Ryoo H. M., Adoptive transfer of human papillomavirus E7-specific CTL enhances tumor chemoresponse through the perforin/granzyme-mediated pathway. Molecular Therapy 2009 17 5 906 913 2-s2.0-67349231629 10.1038/mt.2009.32
68. Tseng C.-W., Trimble C., Zeng Q., Monie A., Alvarez R. D., Huh W. K., Hoory T., Wang M.-C., Hung C.-F., Wu T.-C., Low-dose radiation enhances therapeutic HPV DNA vaccination in tumor-bearing hosts. Cancer Immunology, Immunotherapy 2009 58 5 737 748 2-s2.0-61349201441 10.1007/s00262-008-0596-0
69. Spanos W. C., Nowicki P., Lee D. W., Hoover A., Hostager B., Gupta A., Anderson M. E., Lee J. H., Immune response during therapy with cisplatin or radiation for human papillomavirus-related head and neck cancer. Archives of Otolaryngology-Head and Neck Surgery 2009 135 11 1137 1146 2-s2.0-73249140737 10.1001/archoto.2009.159
70. Vermeer D. W., Spanos W. C., Vermeer P. D., Bruns A. M., Lee K. M., Lee J. H., Radiation-induced loss of cell surface CD47 enhances immune-mediated clearance of human papillomavirus-positive cancer. International Journal of Cancer 2013 133 1 120 129 10.1002/ijc.28015
71. Sarfati M., Fortin G., Raymond M., Susin S., CD47 in the immune response: role of thrombospondin and SIRP-alpha reverse signaling. Current Drug Targets 2008 9 10 842 850 2-s2.0-65849289247